Ettore Squillaci MD, Presenter: Nothing to Disclose

Francesca Bolacchi, Abstract Co-Author: Nothing to Disclose

Marco Antonicoli, Abstract Co-Author: Nothing to Disclose

Simone Altobelli, Abstract Co-Author: Nothing to Disclose

mariangela massaccesi MD, Abstract Co-Author: Nothing to Disclose

Giovanni Simonetti MD, Abstract Co-Author: Nothing to Disclose

Brentuximab vedotinis is a possible treatment option in patients suffering from relapsed and refractory Hodgkin lymphoma (HL). This study evaluates the feasibility of realtime ultrasound elastography (RTE) for monitoring treatment response to brentuximab vedotin in patients with relapsed and refractory HL.

Fifteen consecutive, heavily pretreated patients with relapsed and refractory HL treated with brentuximab vedotin were included in the study. RTE was performed during treatment after a median of 3 cycles (range, 2-5 cycles). Elastographic patterns were given scores of 1–5 according to the percentage of high elasticity (hard) areas in the lymph node. Elastographic patterns 1, 2, 3, 4, and 5 were assigned elastography scores (ES) of 1, 2, 3, 4, and 5, respectively.

The median progression-free survival (PFS) was 14.2 months and PFS at 12 months was 63%. Patients treated with brentuximab vedotin and elastography score of 2 and 3 demonstrated a significantly prolonged PFS compared to patients with elastografic score of 4 and 5. The 1-year PFS was 76% in patients with an elastography score of 2 and 3, whereas patients with an elastography score of 4 and 5 had a worse outcome with a 1-year PFS of 24% (p = 0.015)

Real time Elastography can provide non-invasive, real-time tool for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma.

Real time elastography could be a reliable tool for the assessment of refractory Hodgkin lymphoma response to brentuximab vedotin treatment.

Squillaci, E, Bolacchi, F, Antonicoli, M, Altobelli, S, massaccesi, m, Simonetti, G, Real-time Ultrasound Elastography for Assessment of Response to Brentuximab Vedotin Treatment in Relapsed and Refractory Hodgkin Lymphoma .  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14010350.html